The SGLT2 Inhibitors Market reports delivers an in-depth assessment of market size, share, and emerging trends, offering valuable insights into growth opportunities. It examines market segmentation and definitions, highlighting core components and key drivers of expansion. By applying SWOT and PESTEL analyses, the study evaluates the sector’s strengths, weaknesses, opportunities, and threats, while also considering political, economic, social, technological, environmental, and legal factors. Expert reviews of competitor strategies and recent developments provide a clearer view of regional dynamics and future market trajectories, establishing a strong foundation for strategic planning and informed investment decisions.
What will be the market size of Global SGLT2 Inhibitors Market 2030?
The SGLT2 Inhibitors Market size was valued at around USD 18.41 billion in 2024 and is projected to reach USD 30.34 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 8.68% during the forecast period, i.e., 2025-30
Download Free PDF Brochure: https://www.marknteladvisors.com/query/request-sample/sglt2-inhibitors-market.html
Who are the top companies operating in the Global SGLT2 Inhibitors Market?
The report features prominent companies operating in the SGLT2 Inhibitors Market and the successful strategies they have adopted. It also provides detailed insights into each company’s market share and their role in driving the industry’s growth. As per MarkNtel Advisors, top companies in SGLT2 Inhibitors Market: Astellas, AstraZeneca, Boehringer Ingelheim International, Bristol-Myers Squibb Company, Eli Lilly and Company, Glenmark Pharmaceuticals, Johnson & Johnson (Janssen Pharmaceuticals), Lexicon Pharmaceuticals, Lupin Limited, Merck, Sanofi, TheracosBio, and Others
What is the key factor projected to fuel growth in the Global SGLT2 Inhibitors Market between 2025 and 2030?
High Prevalence of Chronic Diseases – The market demand is driven by the high burden of chronic disorders globally, especially cardiovascular diseases, chronic disorders, and type 2 diabetes. For instance, as per the International Diabetes Federation (2021), there were over 540 million adult patients with type 2 diabetes globally, which is further expected to reach more than 640 million. Similarly, chronic kidney disease (CKD) is also highly prevalent globally, accounting for more than 840 million individuals all around the world. Also, more than 65 million individuals experience heart failure globally.
These are increasing the demand for advanced medication such as the SGLT2 Inhibitors, which can inhibit the action of the SGLT2 protein and are highly effective in overcoming these diseases, thus increasing market growth. It has led to the expansion of the SGLT2-inhibitor-based drugs' active pharmaceutical ingredient plants (API) worldwide. For instance, there are about 40-50 API plants globally that are specific to SGLT2 inhibitors.
Browse Full Research Report: https://www.marknteladvisors.com/research-library/sglt2-inhibitors-market.html
Global SGLT2 Inhibitors Market - Segmentation Analysis
-
By Drug Type (Jardiance [empagliflozin], Farxiga [dapagliflozin], Invokana [canagliflozin], Inpefa [sotagliflozin], Qtern [dapagliflozin/saxagliptin], Others)
-
By Application (Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease [CKD], Others)
-
By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and others
How does the Global SGLT2 Inhibitors Market vary across different geography?
By Region
-
North America
-
South America
-
Europe
-
The Middle East & Africa
-
Asia-Pacific
This Section cover detailed analysis of revenue, market share and growth rate, historical data (2020-23) and forecast (2025-2030) of the following segmentation and geography.
Inquire Before Buying, Connect with our Expertise Today: https://www.marknteladvisors.com/query/talk-to-our-consultant/sglt2-inhibitors-market.html
Comprehensive Table of Contents – Global SGLT2 Inhibitors Market Analysis and Forecast, 2030
-
Table 1: Introduction
-
Table 2: Executive Summary
-
Table 3: Market Regulations, Policies & Standards
-
Table 4: SGLT2 Inhibitors Market Size, Share & Scope, 2020-2030
-
Table 5: Market Trends & Developments
-
Table 6: Market Dynamics (Key Drivers, and Challenges)
-
Table 7: Market Hotspots & Opportunities
-
Table 8: Market Value Chain Analysis
-
Table 9: Market Outlook, 2020-2030
-
Table 10: Market Size & Analysis by Revenues (USD Million):
-
Table 11: Market Size & Forecast 2020-2030 by Segmentation
-
Table 12: Market Size & Forecast 2020-2030 by Geography
-
Table 13: Key Strategic Imperatives for Success & Growth
-
Table 14: Competitor Analysis of SGLT2 Inhibitors Companies
Key Benefits for Industry Participants and Stakeholders
-
Insight into emerging market trends and investment opportunities
-
Understanding of regional market dynamics and competitive landscapes
-
Data-driven forecasts to support strategic decision-making
-
Access to industry benchmarks for performance evaluation
-
Identification of potential risks and growth challenges
Browse More Reports:
-
Bahrain Electric Vehicle Market Research Report: Forecast (2025-2030)
-
Italy Electric Scooter Market Research Report: Forecast (2025-2030)
-
Saudi Arabia Protein Bar Market Research Report: Forecast (2025-2030)
-
Saudi Arabia Ice Cream Market Research Report: Forecast (2025-2030)
About Us:
MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.
We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.
Contact Us:
MarkNtel Advisors
Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India
Contact No: +91 8719999009
Email: sales@marknteladvisors.com
